Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population

Journal of Cutaneous Medicine and Surgery

Volumn 14, Issue 4, 2010, Pages 167-174

  Papp, Kim ^a   Valenzuela, Fernando ^a   Poulin, Yves ^a   Bernstein, Geula ^a   Wasel, Norman ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANADA; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; SEX DIFFERENCE;

ADOLESCENT; ADULT; BODY SURFACE AREA; CANADA; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; PSORIASIS; YOUNG ADULT;

EID: 77955444423     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2010.09066     Document Type: Article

References (63)

1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64 Suppl 2:ii18-23; discussion ii4-5.
2. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008;19:5-21.
3. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003;49 (2 Suppl):S57-61.
4. Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis, June 2009. Available at: http://www.dermatology. ca/psoriasisguidelines (accessed September 28, 2009).
5. Boudreau R, Blackhouse G, Goeree R, Mierzwinski-Urban M. Adalimumab, alefacept, efalizumab, etanercept, and infliximab for severe psoriasis vulgaris in adults: budget impact analysis and review of comparative clinical- and cost-effectiveness Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007. Technology report number 97.
6. Nall L, Gulliver W, Charmley P, Farber EM. Search for the psoriasis susceptibility gene: the Newfoundland Study. Cutis 1999; 64:323-9.
7. Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005;52:23-6.
8. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-96.
9. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136-9.
10. Barisic-Drusko V, Paljan D, Kansky A, Vujasinovic S. Prevalence of psoriasis in Croatia. Acta Derm Venereol Suppl (Stockh) 1989;146: 178-9.
11. Farber EM, Nall L. Epidemiology: natural history and genetics. In: Roenigk HH Jr, Maibach HI, editors. Psoriasis. New York: Marcel Dekker; 1998. p. 107-57.
12. Naldi L. Inflammatory skin diseases IV: psoriasis. In: Strachan DP, editor. The challenge of dermato-epidemiology. Boca Raton (FL): CRC Press; 1997. p. 175-87.
13. Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 1984;10:965-8.
14. Lin XR. Psoriasis in China. J Dermatol 1993;20:746-55.
15. Shao CG, Zhang GW, Wang GC. Distribution of psoriasis in China: a nationwide screening. Proc Chin Acad Med Sci Peking Union Med Coll 1987;2:59-65.
16. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol 1981;61:344-6.
17. Lomholt G. Psoriasis: prevalence, spontaneous course, and genetics [PhD thesis]. Copenhagen: G.E.C. GAD; 1963.
18. Braathen LR, Botten G, Bjerkedal T. Prevalence of psoriasis in Norway. Acta Derm Venereol Suppl (Stockh) 1989;142:5-8.
19. Kavli G, Forde OH, Arnesen E, Stenvold SE. Psoriasis: familial predisposition and environmental factors. Br Med J (Clin Res Ed) 1985;291:999-1000.
20. Kavli G, Stenvold SE, Vandbakk O. Low prevalence of psoriasis in Norwegian Lapps. Acta Derm Venereol 1985;65:262-3.
21. Falk ES, Vandbakk O. Prevalence of psoriasis in a Norwegian Lapp population. Acta Derm Venereol Suppl (Stockh) 1993;182:6-9.
22. Convit J. Investigation of the incidence of psoriasis among Latin American Indians. In: Proceedings of the 13th Congress on Dermatology, Amsterdam; 1962. p. 196.
23. Hellgren L. Psoriasis: the prevalence in sex, age and occupational groups in total populations in Sweden; morphology, inheritance and association with other skin and rheumatic diseases. Stockholm: Almqvist & Wiksell; 1967.
24. Rea JN, Newhouse ML, Halil T. Skin disease in Lambeth. A community study of prevalence and use of medical care. Br J Prev Soc Med 1976;30:107-14.
25. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996;135:533-7.
26. Johnson MT, Roberts J. Skin conditions and related need for medical care among persons 1-74 years: United States, 1971-1974. In: U. S. Department of Health, editor. Data from the National Health Survey, no. 212, DHEW Publication No. (PHS) 79- 1660. Hyattsville (MD): Government Printing Office; 1978. p. 1-72.
27. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20.
28. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007;25:535-46.
29. Ferrandiz C, Bordas X, Garcia-Patos V, et al. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol 2001;15:20-3.
30. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16-7.
31. Wasel N, Poulin Y, Andrew R, et al. A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. J Cutan Med Surg 2009;13:294-302.
32. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol 2008;26:448-59.
33. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50.
34. Ware JE, Kosinski M, Dewey JE, Gandek B. How to score and interpret single-item health status measures: a manual for users of the SF-8™ Health Survey. Lincoln (RI): QualityMetric; 2001.
35. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
36. Ware JE, Kosinski M, Dewey JE, Gandek B. A manual for users of the SF-8 Health Survey. Lincoln (RI): QualityMetric; 2001.
37. Yang M, Wallenstein G, Hagan M, et al. Burden of premenstrual dysphoric disorder on health-related quality of life. J Womens Health (Larchmt) 2008;17:113-21.
38. Ware JE, Kosinski M, Bjorner JB, et al. User's manual for the SF- 36® Health Survey (version 2). 2nd ed. Lincoln (RI): QualityMetric; 2007.
39. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4.
40. Fry L. Psoriasis. Br J Dermatol 1988;119:445-61.
41. Ferrandiz C, Pujol RM, Garcia-Patos V, et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002;46:867-73.
42. Duffin KC, Chandran V, Gladman DD, et al. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol 2008;35:1449-53.
43. Christensen TE, Callis KP, Papenfuss J, et al. Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J Invest Dermatol 2006; 126:2397-403.
44. Gupta MA, Gupta AK. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 1995;34:700-3.
45. Kononen M, Torppa J, Lassus A. An epidemiological survey of psoriasis in the greater Helsinki area. Acta Derm Venereol Suppl (Stockh) 1986;124:1-10.
46. Inerot A, Enerback C, Enlund F, et al. Collecting a set of psoriasis family material through a patient organisation; clinical characterisation and presence of additional disorders. BMCDermatol 2005;5:10.
47. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5.
48. Warren RB, Brown BC, Griffiths CE. Topical treatments for scalp psoriasis. Drugs 2008;68:2293-302.
49. Gupta MA, Gupta AK. Quality of life of psoriasis patients. J Eur Acad Dermatol Venereol 2000;14:241-2.
50. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005;6:383-92.
51. Ramsay B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988;118:195-201.
52. Fried RG, Friedman S, Paradis C, et al. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995;34:101-5.
53. Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002;47:512-8.
54. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
55. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008;7:563-72.
56. Kimball AB, Robinson D, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008;217:27-37.
57. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159:895-902.
58. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008;216:152-5.
59. World Health Organization Global InfoBase: data for saving lives (Canadian data). Available at: http://www.who.int/infobase/ report.aspx? rid5111&iso5CAN (accessed February 10 2009).
60. Martin LM, Leff M, Calonge N, et al. Validation of self-reported chronic conditions and health services in a managed care population. Am J Prev Med 2000;18:215-8.
61. Novak SP, Kroutil LA, Williams RL, Van Brunt DL. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2007; 2:32.
62. Schmitt J, Ford DE. Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis - a structural equations modeling approach. Gen Hosp Psychiatry 2007;29:134-40.
63. De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002;138:1221-7; discussion 7.